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ABSTRACT Transforming growth factors (TGFs) were pu-
rified from serum-free medium conditioned by retrovirus-trans-
formed Fisher rat embryo fibroblasts, mouse 3T3 cells, and two
human melanoma cell lines. The purification of each TGF was
monitored in a radioreceptor assay based on receptor crossreac-
tivity with mouse submaxillary gland epidermal growth factor
(mEGF) and was achieved by gel permeation chromatography of
the acid-soluble TGF-containing activity, followed by reverse-phase
high-pressure liquid chromatography with sequential use of ace-
tonitrile and I-propanol in the presence of aqueous trifluoroacetic
acid. The amino-terminal sequences of rat, mouse, and human
TGFs were determined. Extensive sequence homology was found
among TGF polypeptides from different species and cell types.
Alignment of the amino acid sequences of rat TGF, mEGF, and
human urogastrone (hEGF) reveals statistically significant se-
quence homology. The reported results suggest that TGFs that
compete for binding to the cellular EGF receptor and EGF may
have evolved from a common progenitor.
Polypeptide growth factors that are able to confer the trans-
formed phenotype on normal cells have been termed trans-
forming growth factors (TGFs) (1). The transformed phenotype
is operationally defined (2) by the loss of density-dependent
inhibition of cell growth in monolayer culture, overgrowth in
monolayer culture, characteristic change in cellular morphol-
ogy, and acquisition of anchorage-independent growth. TGFs
have been classified into two categories on the basis of their
biological and physical properties (3). Each member of the type
I TGFs (TGFa) competes with epidermal growth factor (EGF)
for binding to the cellular EGF receptor. In contrast, type II
TGFs (TGFP) display no measurable binding to EGF receptors
but may potentiate the growth-stimulating activity of type I TGFs
in semisolid medium (4). Transformed cells cultured in serum-
free medium produce and release growth factors with the abil-
ity to confer the transformed phenotype on normal fibroblasts
(2) and epithelial cells (5) in vitro. Polypeptides with the prop-
erties of a type I TGF have been isolated and partially purified
from the conditioned medium of Moloney murine sarcoma vi-
rus-transformed mouse 3T3 cells (6), from retrovirus-trans-
formed rat fibroblasts (7), and from certain human tumor cells
(8). A low molecular weight human melanoma-derived type I
TGF (hTGF) has been purified to apparent homogeneity (9).
Both type I hTGF and mouse submaxillary gland EGF (mEGF)
are qualitatively and quantitatively nearly indistinguishable in
competing for binding to (9) and for inducing tyrosine phos-
phorylation of (10) the EGF receptor and in stimulating the
phosphorylation, by A431 human carcinoma and mouse 3Th cell
membranes, of a synthetic tyrosine-containing peptide (11).
We describe in this paper the large-scale purification of low
molecular weight rat and mouse type I TGFs (rTGF and mTGF)
and of hTGF that are produced by Snyder-Theilen feline sar-
coma virus-transformed Fisher rat embryo fibroblasts, Molo-
ney murine sarcoma virus-transformed mouse 3T3 cells, and
two human melanoma cell lines, respectively. The purification
of each TGF was monitored in a radioreceptor assay based on
receptor crossreactivity with mEGF. The amino-terminal se-
quences of the isolated polypeptides are reported. The data
clearly define the structural relationship among these func-
tionally indistinguishable type I TGF polypeptides and estab-
lish unequivocally a structural relationship to EGF.
MATERIALS AND METHODS
Source of TGF. rTGF, mTGF, and hTGF were purified from
the serum-free medium conditioned respectively by Fisher rat
embryo fibroblasts FRE C110, a subelone of FRE 3A (12), non-
productively transformed by Snyder-Theilen feline sarcoma vi-
rus (13); by a Moloney murine sarcoma virus-transformed mouse
3T3 cell line, 3B11-IC (14); and by two human metastatic mel-
anoma lines, A2058 (8) and A375 (15). Cells were grown in 2-
liter plastic roller bottles containing Dulbecco's modified Ea-
gle's medium supplemented with 10% calf serum and subse-
quently maintained in serum-free Waymouth's medium as de-
scribed (2). Serum-free conditioned medium was collected every
24 hr for a 3-day period and clarified by continuous flow cen-
trifugation. The supernatant was concentrated (16), and this
concentrate of conditioned medium was the starting material
for the purification of TGFs.
Purification of TGF. rTGF and mTGF were prepared es-
sentially as described (9) for the purification of the melanoma-
derived hTGF. The retentate after ultrafiltration of condi-
tioned medium was dialyzed against 0.1 M acetic acid, and the
supernatant, after centrifugation, was concentrated by lyoph-
ilization and reconstituted in 1 M acetic acid for subsequent gel
permeation chromatography on a column (2.5 X 85 cm) of Bio-
Gel P-10 (200-400 mesh, Bio-Rad Laboratories). The column
was equilibrated with 1 M acetic acid. Fractions comprising the
major EGF-competing activity and having an apparent molec-
ular weight of approximately 7,000 were pooled and lyophi-
lized.
Abbreviations: TGF, transforming growth factor; rTGF, mTGF, and
hTGF, low molecular weight rat, mouse, and human transforming growth
factors [the term mTGF will refer in this communication to the low mo-
lecular weight sarcoma growth factor (6)]; EGF, epidermal growth fac-
tor; mEGF, mouse submaxillary gland EGF; hEGF, urogastrone.
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The final purification of rTGF, mTGF, and hTGF was
achieved by reverse-phase HPLC. The chromatography system
has been described (17). The separations were performed on a
,4Bondapak C18 column (10-gim particle size, 0.39 X 30 cm,
Waters Associates). The mobile phase was 0.05% trifluoroacetic
acid, and the mobile-phase modifier was acetonitrile containing
0.045% trifluoroacetic acid. The concentration of acetonitrile
was increased linearly (0.083%/min) during 2 hr at a flow rate
of 1 ml/min at 40'C for elution of peptides. TGF-containing
pools were lyophilized and reconstituted in 0.05% trifluoroace-
tic acid and were rechromatographed on the same column, with
1-propanol containing 0.035% trifluoroacetic acid as the mo-
bile-phase modifier. The 1-propanol concentration was in-
creased linearly (0.05%/min) during 2 hr at a flow rate of 1 ml/
min at 40'C. Pools of fractions comprising the major EGF-com-
peting activity were lyophilized.
Assay for TGF. TGF was quantitated in a radioreceptor as-
say based on receptor crossreactivity with mEGF. Purified
mEGF (18) was labeled with Nal251 (l25I-EGF) by a modifi-
cation of the chloramine-T method (19) as described (6). The
1251-EGF binding assay was performed on Formalin-fixed A431
(15) human carcinoma cells (8 x 103) in Micro Test II plates
(Falcon) (9). The concentration of TGF was expressed in nano-
gram equivalents of mEGF per ml and was based on the amount
of TGF required to produce equal inhibition of 125I-EGF bind-
ing to A431 cells as a known amount of unlabeled mEGF.
Amino Acid Sequence Determination of TGF. For amino-
terminal sequence analysis, rTGF (3 ,g) was reduced with di-
thiothreitol (20 mM) in 100 ,ul of 0.4 M Tris HCI/6 M guani-
dine-HCI/0.1% Na2EDTA, pH 8.5, for 2 hr at 50°C and sub-
sequently S-carboxamidomethylated with iodoacetamide (45 mM)
for 30 min at 22°C. The S-carboxamidomethylated rTGF was
desalted on a ,uBondapak C18 column. Peptide was eluted with
a gradient of aqueous acetonitrile containing 0.045% trifluo-
roacetic acid. The concentration of acetonitrile was increased
linearly (1%/min) during 1 hr at a flow rate of 1 ml/min at 40°C.
Automated sequence analyses (20) of S-carboxamidomethyl-
ated rTGF and unmodified mTGF and hTGF were performed
with a gas/liquid solid-phase microsequenator (21). Sequenator
fractions were analyzed by reverse-phase HPLC (22).
Statistical Analyses for Relatedness of the TGF Amino Acid
Sequence to Other Proteins. The partial amino acid sequence
of rTGF was compared with each known sequence stored in a
protein sequence data base (23) using the SEARCH program
(24). Homologies between the rTGF sequence and those of
mEGF (25) and human urogastrone (hEGF) (26) were estab-
lished by using the program ALIGN (27). The program ALIGN
determines a best alignment of two protein sequences (includ-
ing gaps) by computing the maximum match score using the
mutation data matrix (250 PAMs) (28) with a matrix bias pa-
rameter and a penalty parameter each set to 6. This score is
then compared with the highest possible scores obtained by
aligning pairs of 100 random formulations having the same amino
acid composition as the two real sequences. The scores of the
randomized sequences form a normal distribution for which the
mean and standard deviation are calculated. The probability
that the score for the real sequences is derived from this normal
distribution is then obtained.
RESULTS
Purification of TGF. Purified preparations of a low molec-
ular weight rTGF, mTGF, and hTGF were obtained from the
conditioned medium of retrovirus-transformed rat and mouse
fibroblasts and two human melanoma cell lines, respectively.
The purification was achieved by gel permeation chromatog-
raphy of the acid-soluble EGF-competing activity on Bio-Gel
P-10 in 1 M acetic acid, followed by reverse-phase HPLC on
,uBondapak C18 support with sequential use of a linear gradient
of aqueous acetonitrile and 1-propanol containing trifluoroace-
tic acid. Typical elution patterns of the final purification step
of rTGF, mTGF, and hTGF are shown in Fig. 1. EGF-com-
peting activity copurified with a distinct absorbance peak, in-
dicated with a bar, and was effectively separated from contam-
inating UV-absorbing material. The major protein peak in rTGF,
l
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FIG. 1. Final purification of rTGF (A), mTGF (B), and hTGF (C) by
reverse-phase HPLC on ,ABondapak C18 support. The elution of pep-
tides was achieved with a 10-min linear gradient of 0-8% 1-propanol,
followed by a 2-hr linear gradient of8-14% 1-propanol containing 0.035%
trifluoroacetic acid. The 1-propanol concentration was increased (0.05%/
min) during 2 hr at a flow rate of 1 ml/min at 40°C. UV-absorbing ma-
terial was detected at 206 nm. The horizontal bar indicates pooled TGF.
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mTGF, and hTGF preparations was eluted from a gBondapak
C18 column under standard conditions between 48 and 55 min.
Gel permeation chromatography on Bio-Gel P-10 provided
a separation of the low molecular weight TGFs from larger mo-
lecular weight TGFs and reduced the load of protein applied
to a pJBondapak C18 column in the following purification step.
The low molecular weight TGFs represented 45-80% of the
initial total EGF-competing activity. Reverse-phase HPLC of
TGFs on tBondapak C18 support in the following two purifi-
cation steps was very efficient, each step in a typical prepa-
ration giving a recovery range of 80-100%. The final recovery
of the low molecular weight TGFs was approximately 70%, based
on the maximal total EGF-competing activity detected during
the course of the purification. The average yield per liter of
conditioned medium of purified rTGF was 90 ng, of mTGF was
50 ng, and of hTGF was 10 ng. This calculation is based on the
specific activity determined for isolated TGFs and on the as-
sumption that the EGF-competing activity measured in the ra-
dioreceptor assay reflects levels of total large and low molecular
weight TGFs only. No immunoreactive mEGF was detected in
conditioned medium (2).
Purity of TGF. The purity of rTGF, mTGF, and hTGF sug-
gested by the chromatographic elution profiles was assessed in
the EGF radioreceptor assay and by amino acid sequence anal-
ysis. rTGF, mTGF, and hTGF competed with 125I-EGF for the
EGF receptor sites on A431 human carcinoma cells and were
qualitatively and quantitatively nearly indistinguishable from
mEGF. Hence, the final TGF preparations were believed to be
highly purified and close to homogeneity. A single amino-ter-
minal sequence was determined by automated Edman degra-
dation for rTGF, mTGF, and hTGF. Any unblocked minor
peptide sequence present at >5% could have been detected by
the methods used. The homogeneity of hTGF was confirmed
in addition by analytical NaDodSO4/polyacrylamide gel elec-
trophoresis. The purified preparation gave one major polypep-
tide band (9).
Amino-Terminal Sequence of TGF. Automated Edman
degradation of rTGF was performed with 300 pmol (based on
the initial yield of identified phenylthiohydantoin-amino acids)
of the S-carboxamidomethylated derivative. Unambiguous
identification of phenylthiohydantoin derivatives of amino acids
was possible up to residue 43, except at positions 26, 30, 36, 40,
and 42, where no amino acid could be assigned. The residues
at positions 28 and 37 were tentatively assigned. The amino-
terminal amino acid sequence of rTGF is given in Fig. 2.
The amino-terminal sequence of mTGF was determined with
550 pmol of unmodified mTGF. Amino acid residues at posi-
tions 8, 16, 21, 30, 32, 34, and 36 were not identified in this
experiment. The residues at positions 26, 28, and 37 were ten-
tatively assigned. The partial amino-terminal amino acid se-
quence of mTGF is shown in Fig. 2.
The sequence of melanoma-derived hTGF was determined
1 5 10 15 20
twice. Edman degradation of unmodified hTGF, isolated from
A375-conditioned medium, was performed with 120 pmol for
34 cycles. The results are shown in Fig. 2. Amino acid residues
at positions 8, 16, 21, 22, 23, 26, 30, 32, and 34 were not iden-
tified. Residues at positions 20, 24, 28, and 33 were tentatively
assigned. The amino-terminal sequence of unmodified hTGF,
isolated from A2058-conditioned medium, was determined with
75 pmol. Identified phenylthiohydantoin derivatives of amino
acids up to residue 19 were identical with those established in
the partial sequence of A375-derived hTGF.
Amino-Terminal Sequence Homology of rTGF with mEGF
and hEGF. The sequence of rTGF was entered into the protein
data base of the Atlas of Protein Sequence and Structure in Jan-
uary 1983, and the SEARCH program was used to compare res-
idues 1-25 and 19-43 against the current protein data base,
containing 2,145 protein sequences. Statistically significant se-
quence homology was found only between mEGF, hEGF, and
rTGF. The possible structural relatedness between these poly-
peptides was statistically analyzed by using the program ALIGN.
The alignment of the amino-terminal sequence of rTGF with
sequences of mEGF and hEGF is shown in Fig. 3. The align-
ment scores, A, from intercomparisons of rTGF, mEGF, and
hEGF are shown in Table 1. The probabilities of rTGF being
so similar by chance to mEGF and hEGF are <10-11.
DISCUSSION
Type I TGFs were isolated from serum-free medium condi-
tioned by retrovirus-transformed rat and mouse fibroblasts and
human melanoma cells. The purification of TGFs was.moni-
tored in a radioreceptor assay developed for mEGF and was
achieved by gel permeation chromatography and reverse-phase
HPLC with sequential use of mobile-phase modifiers of dif-
ferent solvent polarity in the presence of the same hydrophobic
counterion. TGFs could be directly identified in the last pu-
rification step by determining the characteristic elution posi-
tions of rTGF, mTGF, and hTGF when chromatographed on
p.Bondapak C18 support (Fig. 1) and quantitated by integrating
peak areas. The recovery of isolated TGFs from conditioned
medium was about 70%.
Comparison of the amino-terminal sequences of rTGF,
mTGF, and hTGF revealed a high degree of sequence ho-
mology. When the sequences were aligned, as shown in Fig.
2, all of the identified residues in rTGF and mTGF were iden-
tical. A comparison of the amino-terminal sequence of rTGF
with the amino-terminal sequence of hTGF indicated that hTGF
and rTGF differed from each other by at least three amino acid
substitutions. The sequence of hTGF differed from that of rTGF
by substitution of aspartic acid for lysine in position 7, a con-
servative substitution of phenylalanine for tyrosine in position
15, and a substitution in position 23, although not positively
identified; 23 of 26 amino acid positions, or 88%, are identical.
25 30 35 40
rTGF V V S H F N K C P D S H T 0 Y C F H G T C R F L V X E(E)K X A C V C H X(G)Y V X V X C
mTGF V V S H F N K X P D S H T 0 Y .X F H G T X R F L V(Q)E(E)K X A X V X H X(G)Y V X
hTGF V V S H F N D X P D S H T 0 F X F H G(T)X X X(L)V X E(E)K X A X(V)X
FIG. 2. Alignment of amino-terminal sequences of rTGF, mTGF, and hTGF. Amino acid residues are given in single letter code (29). Residues
in the amino acid sequence of hTGF that differ from those in sequences of rTGF and mTGF are underlined. X, Unidentified residue.
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FIG. 3. Alignment of amino acid sequences of rTGF, mEGF (25), and hEGF (26). Numbers in parentheses denote actual residues compared.
Amino acid residues are given in single letter code (29). Hyphens indicate gaps introduced to bring homologous regions of the structures into align-
ment. Boxes indicate regions or residues of identity in rTGF, mEGF, and hEGF. Residues differing in the genetic code by only one base are un-
derscored by an asterisk.
Edman degradation of unmodified mTGF and hTGF did not
give identifiable phenylthiohydantoin-amino acids for residues
8, 16, 21, 32, and 34. The demonstrated sequence similarity of
rTGF with mTGF and hTGF can be taken as presumptive evi-
dence that half-cystine/cysteine residues, which are nonde-
tectable on analysis of native proteins, occupied these positions
in the amino acid sequences of mTGF and hTGF.
The data presented here indicate that rTGF, mTGF, and
hTGF may differ from each other by only a few amino acid sub-
stitutions. These results establish that TGFs produced by re-
trovirus-transformed rat and mouse fibroblasts and two human
melanoma cell lines are highly conserved structurally and func-
tionally among different species and cell types. The similarities
in the amino-terminal sequences of rTGF and mTGF produced
by cells transformed by two different retroviruses containing
genetically distinct acquired cellular sequences favor the con-
clusions that TGFs represent cellular rather than viral gene
products and that TGF production may be relatively common
in transformed cells.
An interesting feature of the amino-terminal sequence of rTGF
is the structural relationship to hEGF and mEGF. A computer-
assisted alignment (Fig. 3) of the first 43 amino acid residues
of rTGF with those of hEGF resulted in 17 common amino acid
residues out of 36 possible comparisons, yielding an alignment
score of 7.85 SD. When the sequences of rTGF and mEGF
were compared, an alignment score of 7.24 SD was obtained,
which is well above the range of random chance. Moreover,
there is considerable conservation of third-base-coding assign-
ments. Between the amino-terminal sequences of rTGF and
hEGF, 8 of 36 residues differed in the genetic code by only one
base; 10 of 36 third-base identities are found between rTGF
and mEGF. Alignment of the amino-terminal sequences of rTGF
with hEGF and mEGF required a single deletion between res-
idues 18 and 20 to bring all six cysteines into register, thus
maintaining the overall disulfide bond configuration.
The observed homology between type I TGFs and EGFs
Table 1. Alignment scores for comparison of rTGF, mEGF,
and hEGF
Alignment score,
SD units
rTGF mEGF
(1-43) (1-42)
rTGF (1-43) - 7.24
hEGF (1-42) 7.85 13.86
Alignment scores were obtained by using the program ALIGN.
Numbers in parentheses denote actual residues compared. The mEGF
sequence was from ref. 25, the hEGF sequence was from ref. 26.
emphasizes evolutionary relationship and suggests that type I
TGFs and EGFs may have evolved through a process of gene
duplication from a common ancestral molecule. The divergence
between type I TGFs and EGFS may have occurred before the
appearance of the vertebrates, provided that the rate of evo-
lutionary change was similar in the two polypeptides. The de-
gree of homology detected between type I TGFs and mEGF
is not sufficient to cause immunologic crossreactivity, thus con-
firming earlier observations (2). Likewise, type I mTGF does
not compete with mEGF for binding tor the specific and sat-
urable EGF-binding protein (30) (unpublished data), which
functions in the enzymatic processing of active mEGF from an
inactive precursor (31). Therefore, type I TGFs and mEGF ap-
pear to share structurally a common cellular receptor binding
region only. The large sequence differences observed between
type I TGFs and EGFs suggest that during peptide hormone
evolution, type I TGFs acquired additional structural proper-
ties. Evidence was presented (32) that type I TGFs can bind
specifically to a different set of receptors on normal rat kidney
cells than does mEGF. The interaction of type I TGFs with this
receptor is thought to induce the transformed phenotype ex-
pressed by these untransformed cells.
A physiological role of type I mTGF and rTGF in neoplastic
transformation was suggested largely by correlating their pro-
duction with the expression of the transformed phenotype in
rodent cells by use of well-characterized viral mutants (33, 34)
but has not yet been shown for type I hTGF produced by hu-
man tumor cells. The expression of type I TGFs in neoplastic
tissues (35) and the ectopic production by transformed cells may
be a benefit to the cell and could then play a vital part in the
growth and development of tumors.
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